번호 | 제목 | 첨부파일 | 등록일 | 조회 |
---|---|---|---|---|
57 | FDA Seeks Comment on Quality Considerations for Topical Ophthalmic Dr... | 2023.11.10 | 710 | |
56 | FDA addresses use of remote interactive evaluations in post-pandemic ... | 2023.11.10 | 558 | |
55 | FDA guidance calls for testing all alcohol based products for methano... | 2023.11.10 | 535 | |
54 | Single use Bioreactors gain popularity worldwide | 2023.11.10 | 452 | |
53 | How much air does a cleanroom need? | 2023.10.13 | 571 | |
52 | Risk Tool Selection With ICH Q9(R1) In Mind | 2023.10.13 | 670 | |
51 | FDA issues draft guidance on post-warning letter meetings under GDUFA... | 2023.10.13 | 638 | |
50 | 5 Best Practices For Responding To FDA Form 483 Inspection Observatio... | 2023.10.13 | 598 | |
49 | Cleanrooms: solving the mystery of recurring low level contamination | 2023.09.07 | 618 | |
48 | The possible Impact of Artificial Intelligence on the Role of the Qua... | 2023.09.07 | 566 |